Matthew Venezia
Stock Analyst at Alliance Global Partners
(4.10)
# 1,555
Out of 4,399 analysts
12
Total ratings
36.4%
Success rate
49.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Venezia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTHI NeOnc Technologies Holdings | Initiated Coverage: Buy | $13 | $4.46 | +191.48% | 1 | May 19, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $51 | $26.01 | +96.08% | 6 | May 14, 2026 | |
| TSX: APS Aptose Biosciences Inc. | Downgraded: Hold | $17.44 → $2.41 | $2.33 | +3.43% | 2 | Nov 24, 2025 | |
| PLUR Pluri | Initiated Coverage: Buy | $12 | $2.38 | n/a | 1 | Jun 2, 2025 | |
| CBUS Cibus | Reiterated: Buy | $24 | $1.22 | n/a | 2 | May 9, 2025 |
NeOnc Technologies Holdings
May 19, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $4.46
Upside: +191.48%
Capricor Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $51
Current: $26.01
Upside: +96.08%
Aptose Biosciences Inc.
Nov 24, 2025
Downgraded: Hold
Price Target: $17.44 → $2.41
Current: $2.33
Upside: +3.43%
Pluri
Jun 2, 2025
Initiated Coverage: Buy
Price Target: $12
Current: $2.38
Upside: n/a
Cibus
May 9, 2025
Reiterated: Buy
Price Target: $24
Current: $1.22
Upside: n/a